BMS' head and neck cancer hopes take a hit with Opdivo-Yervoy trial flop
fiercepharma | April 25, 2019
Bristol-Myers Squibb already has one Opdivo approval in previously treated head and neck cancer, but it won’t make that two. The company, which was testing its immuno-oncology star alongside Yervoy in previously treated patients whose disease had recurred or spread, said Thursday that the pair had failed to outdo Opdivo on its own. For now at least, Bristol isn’t sharing details on the phase 2 miss. But one thing is clear: The regimen won’t be backing up Opdivo in second-line head and neck cancer, where it’s currently battling Merck’s Keytruda.